ライフサイエンスコーパス: palliation

1 th, 7 converted after initial univentricular palliation).

2 d be reserved for an analysis of post-Fontan palliation.

3 y can be performed safely and offers durable palliation.

4 urs frequently in patients undergoing Fontan palliation.

5 ell transplantation, and supportive care and palliation.

6 verse outcomes in patients undergoing Fontan palliation.

7 2 surgical Norwood procedures before stage 2 palliation.

8 n delivery was similarly lower in the hybrid palliation.

9 cure, use of experimental therapies, and/or palliation.

10 diotherapy (WBRT) is a critical component of palliation.

11 ntage of patients with successful worst pain palliation.

12 n in mind allowing better and longer-lasting palliation.

13 drenalectomies due to tumor extension or for palliation.

14 have favorable outcomes after BDG or Fontan palliation.

15 linical impact on patients undergoing Fontan palliation.

16 modynamic stability and survival to stage II palliation.

17 peutics has limited interventions to symptom palliation.

18 cusing on the emergent methods of endoscopic palliation.

19 c disease, but chemotherapy can also provide palliation.

20 isease, this regimen provides at best modest palliation.

21 patients biliary drainage is the mainstay of palliation.

22 an interatrial communication before surgical palliation.

23 nical Context The treatment goal for CRPC is palliation.

24 ally not the final stage of single-ventricle palliation.

25 ial in selected patients early after Norwood palliation.

26 in the patient population undergoing Fontan palliation.

27 me overload characteristic of prior forms of palliation.

28 ies such as radioimmunotherapy and bone pain palliation.

29 or infections, improve function, or provide palliation.

30 es requiring aggressive treatment to achieve palliation.

31 ns of improving outcomes of single ventricle palliation.

32 hemotherapy and surgery only if required for palliation.

33 d's cancer deaths occur without treatment or palliation.

34 specified for patients with single ventricle palliation.

35 o help improve cancer outcomes, control, and palliation.

36 .5% for those discharged with univentricular palliation.

37 riod between stage I palliation and stage II palliation.

38 here is virtually no treatment option beyond palliation.

39 surgical interventions, rehabilitation, and palliation.

40 hypoplastic left heart syndrome after Fontan palliation.

41 ic left heart syndrome patients after Fontan palliation.

42 e prevention, treatment, rehabilitation, and palliation.

43 ne-third (220 of 675) had undergone previous palliation.

44 nd prednisone resulted in significantly more palliation (157 of 349 [45.0%] patients vs 47 of 163 [28

45 .0005) and faster palliation (median time to palliation 5.6 months [95% CI 3.7-9.2] vs 13.7 months [5

46 nging chemotherapy over treatment focused on palliation (67% vs. 64%; z = -1.79; p = .07) and to want

47 D but chose inotropes (15 patients), and for palliation (98 patients).

48 Successful palliation also appears to be related to the percentage

49 megestrol acetate provided superior anorexia palliation among advanced cancer patients compared with

50 ival and reintervention rates after stage II palliation, anatomic and physiologic variables at pre-Fo

51 imensional echocardiography (3DE) prestage 1 palliation and (2) TR is associated with reduced surviva

52 the intensive care unit, 13 (68%) initiated palliation and 5 (42%) documented code status.

53 ntinually walk a fine line between providing palliation and administering treatments that lead to exc

54 g the transition from active intervention to palliation and finally, end of life care.

55 racil-based regimens, especially in terms of palliation and functioning.

56 Pain palliation and global quality of life (QOL) were the two

57 as created a range of choices for treatment, palliation and improved life expectancy.

58 BRS decreased with previous palliation and increasing patient age.

59 herapeutic applications, including bone pain palliation and intravascular radiation therapy.

60 genital heart disease, as opposed to initial palliation and later repair, is now commonplace.

61 k 13 in pain severity and interference; pain palliation and progression at week 13; time to pain prog

62 ive procedure for select patients, providing palliation and prolonging survival.

63 Liver transplantation can provide effective palliation and should be considered in carefully selecte

64 rt disease during the period between stage I palliation and stage II palliation.

65 Survival after stage II palliation and subsequent Fontan completion is equivalen

66 amic therapy using porfimer (P-PDT) improves palliation and survival in nonresectable hilar bile duct

67 Timely surgical intervention may allow palliation and the ability to pursue subsequent systemic

68 ith significant interaction between stage of palliation and treatment group.

69 By multivariable analysis, prior palliation and younger age at repair were predictive of

70 Fifteen patients received nonsurgical palliation, and 30 patients underwent resection of their

71 alth promotion and prevention, survivorship, palliation, and bereavement.' Supportive care can be cla

72 study was to determine survival, adequacy of palliation, and complications after SEMS placement as so

73 ; other endpoints included toxicity, symptom palliation, and quality of life.

74 Results for quality of life, symptom palliation, and tolerability are presented here.

75 sectable disease, and the recent thoughts on palliation are discussed.

76 ronic heart failure that results from failed palliation are limited, in part, by the mammalian heart'

77 ior treatment, extent of tumor, and need for palliation are the most important factors in the decisio

78 Support and palliation are the only current therapies.

79 tion of newborns undergoing single-ventricle palliation are unclear.

80 trend for longer survival time, and similar palliation as with P-PDT.

81 fy risk factors for failure of cavopulmonary palliation at elevated altitude.

82 ingle-stage procedure (n=186), after initial palliation at our center (n=74), or after surgery elsewh

83 ents in the enzalutamide group reported pain palliation at week 13 versus one (7%) of 15 in the place

84 noma esophagus patients require some form of palliation because of locally advanced stage or distant

85 s with DILV or TA-TGA who underwent surgical palliation between 1983 and 2002.

86 e-ventricle physiology who underwent stage I palliation between 2004 and 2010, 75 (69%) infants (Norw

87 tatistically significant differences in pain palliation between the treatment arms.

88 several centers have performed second-stage palliation - bidirectional Glenn or hemi-Fontan procedur

89 delivery was markedly reduced in the hybrid palliation (Blalock-Tausig shunt 591, right ventricle-to

90 for massive splenomegaly (>1500 g) provides palliation but is associated with a high rate of periope

91 tion occurred frequently early after Norwood palliation but normalized with higher FiO2 or PEEP.

92 of androgen production and function provides palliation but not cure in men with prostate cancer (PCa

93 ive therapies continue to be used mostly for palliation, but have also been used with curative intent

94 long life by weeks or months and may provide palliation, but it is not curative.

95 gans, and ultimately they led to the cure or palliation by liver transplantation of more than 2 dozen

96 (e.g., familial hyperlipoproteinemia) whose palliation by portal diversion presaged definitive corre

97 In addition to surgery for cure or palliation (by excision and a variety of other cytoreduc

98 eight at which repair or further more stable palliation can be safely achieved.

99 Previously reserved for palliation, chemotherapy is now also a central component

100 The heart team believed surgical palliation conferred high operative risk due to the pati

101 hort study enrolled 522 patients with Fontan palliation consisting of an atriopulmonary connection (A

102 Staged palliation culminating in the Fontan procedure has resul

103 Importantly, age at Stage II palliation decreased from Era 1 to Era 3 (7.1 vs. 5.9 mo

104 At initial palliation, demographic, clinical variables, and pulmona

105 in tumours with current therapies limited to palliation due to therapeutic resistance.

106 complex defects that would require surgical palliation (e.g., functional univentricular heart).

107 Male sex, pulmonary atresia, and previous palliations emerged as predictors for larger AO dimensio

108 tients with HLH, it provides only short-term palliation even when combined with pulmonary artery band

109 Freedom from palliation failure, defined as death, transplant, BDG/Fo

110 s in service organization to improve patient palliation, family grieving, and allocation of ICU beds.

111 The Fontan procedure is a successful palliation for children with single-ventricle physiology

112 ost patients require some type of endoscopic palliation for dysphagia during the course of their illn

113 However, palliation for HLHS is a three-stage process and final j

114 vs. balloon valvotomy, shunt type in staged palliation for hypoplastic left heart syndrome (HLHS), a

115 enting, the hybrid approach achieves stage 1 palliation for hypoplastic left heart syndrome with diff

116 n infants requiring 3-stage single-ventricle palliation for hypoplastic left heart syndrome, attritio

117 perfusion in patients undergoing first-stage palliation for hypoplastic left heart syndrome.

118 n aortic valvuloplasty; shunt type in staged palliation for hypoplastic left heart syndrome; strategi

119 ative cost study of PDA stent or BT shunt as palliation for infants with ductal-dependent pulmonary b

120 ow-dose HDR brachytherapy provides excellent palliation for local control of acral CTCL lesions, offe

121 ablation and chemotherapy provide effective palliation for most patients with advanced prostate canc

122 In general, devices provide useful palliation for otherwise uncontrollable seizures, but wi

123 may become important components of improving palliation for patients with advanced disease.

124 The cornerstone of palliation for patients with R/M HNSCC is a platinum-bas

125 ontan procedure is the culmination of staged palliation for patients with univentricular physiology.

126 RECENT FINDINGS: Infants following palliation for single ventricle physiology have persiste

127 utcomes of patients undergoing cavopulmonary palliation for single ventricle physiology may be impact

128 t been the experience in newborns undergoing palliation for single-ventricle defects, in particular,

129 ot to be curative but to provide nonsurgical palliation for the symptoms of gastric or colonic obstru

130 o recovery and survival of infants following palliation for univentricular hearts.

131 tinely when a patient is undergoing surgical palliation for unresectable periampullary carcinoma.

132 nsecutive patients undergoing univentricular palliation from 1990 to 2008, predictors of mortality we

133 review of 771 patients who underwent Fontan palliation from 1992 to 2009.

134 therapy guided by ERCP may provide improved palliation from biliary obstruction in the future.

135 ith either of the Norwood models, the hybrid palliation had higher pulmonary-to-systemic flow ratio a

136 Staged surgical palliation has dramatically improved survival, yet event

137 This traditional 3-stage surgical palliation has seen several innovations in the past deca

138 prospective randomized trials of endoscopic palliation have demonstrated that late gastric outlet ob

139 t consisted of a functional single-ventricle palliation in 38 patients (83%) and biventricular repair

140 This study examined survival after surgical palliation in children with single-ventricle physiology.

141 and with improved survival after first-stage palliation in comparison with patients diagnosed after b

142 The staged palliation in HLHS may be a risk factor particularly for

143 on therapy (WBRT) offers tumor shrinking and palliation in many cases, but it has been speculated tha

144 This study evaluated endoscopic palliation in patients with hilar cholangiocarcinoma usi

145 logy, and treatment of symptoms that require palliation in patients with terminal cancer.

146 n declines) with similar global QOL and pain palliation in the MP arm.

147 val for patients with HLHS undergoing staged palliation increased significantly.

148 epilepsy, muscle spasm, alcohol withdrawal, palliation, insomnia, and sedation as they allostericall

149 h-quality cancer care include integration of palliation into cancer care, advance care planning, sent

150 Failed single-ventricle palliation is a growing indication for heart transplanta

151 Palliation is achieved by fluid drainage, but the most e

152 Very early palliation is also predicted to quickly yield near total

153 volume and flatter bending angle prestage 1 palliation is associated with TV failure at medium-term

154 plications of the stages of single ventricle palliation is critical.

155 EC) providing clinical benefit with improved palliation is highly desirable.

156 lected patients, a functional univentricular palliation is indicated in those with major straddling a

157 procedure carries high risk, and duration of palliation is poor.

158 hunt to improve survival to the second-stage palliation is unknown.

159 ry, especially after failed single-ventricle palliation, is presenting new obstacles that may start r

160 For others, palliation may be achieved through additional surgical a

161 and absent central pulmonary arteries, good palliation may be achieved, but repeated angioplasty is

162 This palliation may be intended for the life of the patient i

163 Patients who have undergone the Fontan palliation may develop ventricular dysfunction and arrhy

164 the diseased heart as an adjunct to surgical palliation may provide some benefits over surgery alone

165 s vs 47 of 163 [28.8%]; p=0.0005) and faster palliation (median time to palliation 5.6 months [95% CI

166 Symptomatic adults with the Fontan palliation (n = 29) underwent invasive cardiopulmonary e

167 F with pulmonary stenosis (n=4), post-Fontan palliation (n=5), and other complex congenital heart dis

168 f intensified doxorubicin and ifosfamide for palliation of advanced soft-tissue sarcoma unless the sp

169 biliary stent is the modality of choice for palliation of biliary obstruction.

170 Palliation of bone pain can be achieved in men with andr

171 l treatment benefit compared with placebo in palliation of bone pain or reduction of SREs.

172 all survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse re

173 rn in radioimmunotherapy and in radionuclide palliation of bone pain.

174 Progress in the palliation of bony metastases has resulted in a decrease

175 ew therapeutic approaches for prevention and palliation of cardiac disease and have raised new questi

176 t of 5-year-old children following repair or palliation of CHD.

177 ques and devices are being developed for the palliation of children with a single ventricle.

178 ssion tube allows a low-tech approach to the palliation of colonic obstruction.

179 an procedure is the definitive operation for palliation of complex congenital heart disease with sing

180 indispensable modality in the treatment and palliation of complications from pancreatic adenocarcino

181 on is a recognized complication after Fontan palliation of congenital heart disease.

182 Etanercept may be useful for palliation of constitutional symptoms in MMM.

183 offers the potential for cure, control, and palliation of disease in greater than 50% of patients wi

184 , the study also was designed to compare the palliation of disease-related symptoms.

185 Many modalities of palliation of dysphagia are available, but the procedure

186 ng results and the most suitable therapy for palliation of dysphagia in a given patient.

187 ween years 2005 and 2015 on various modes of palliation of dysphagia in carcinoma esophagus were stud

188 th least morbidity, mortality, and long-term palliation of dysphagia needs to be chosen for the patie

189 r radiotherapy or chemotherapy for long-term palliation of dysphagia with good quality of life.

190 s study aims to discuss the recent trends in palliation of dysphagia with promising results and the m

191 of SEMS (uncovered or partially covered) for palliation of extrahepatic bile duct obstruction initial

192 Endoscopic stents are placed for palliation of extrahepatic bile duct obstruction.

193 For endoscopic palliation of gastric outlet obstruction, enteral self-e

194 SEMS insertion for the palliation of hilar cholangiocarcinoma offers higher tec

195 Secondly, we examine new results for palliation of HLHS.

196 y 4 decades ago, the progress in the 3-stage palliation of hypoplastic left heart syndrome and relate

197 First-stage palliation of hypoplastic left heart syndrome has been p

198 Palliation of intractable abdominal pain can safely be p

199 ents were placed as clinically indicated for palliation of jaundice and to potentially facilitate neo

200 c disease and for patients with the need for palliation of local symptoms, and may be considered as a

201 (8) in metastatic disease, surgery only for palliation of major symptoms; (9) surgeons experienced i

202 xpandable metal stents (CSEMS), intended for palliation of malignant biliary obstruction, have been u

203 igned, uncovered metal biliary stent for the palliation of malignant biliary obstruction.

204 go to specialty in the early management and palliation of malignant bowel obstruction.

205 Metal biliary stents continue to be used for palliation of malignant distal biliary obstruction with

206 f removing gastric neoplasms, and endoscopic palliation of malignant gastric outlet obstruction via s

207 Colonic stenting was introduced for palliation of malignant large-bowel obstruction (MLBO) m

208 Palliation of malignant strictures has improved with adv

209 rd endoscopic and percutaneous approaches to palliation of malignant strictures of the bile duct.

210 iepileptic medications are commonly used for palliation of mass effect and seizures, respectively.

211 f androgen deprivation therapy (ADT) for the palliation of men with androgen-sensitive disease.

212 for treatment of benign bone tumors and for palliation of metastases involving bone and soft-tissue

213 nsistently as having low appropriateness for palliation of metastatic bony pain compared with opioid

214 Measures of delay, control, and palliation of metastatic disease such as pain response,

215 EMS seem to be an appropriate technology for palliation of oesophageal cancer in resource-limited set

216 provement in clinical symptoms and excellent palliation of pain can be achieved.

217 oablation is a safe and effective method for palliation of pain due to metastatic disease involving b

218 t are approved in the USA and Europe for the palliation of pain from metastatic bone cancer, whereas

219 iver, prostate, and brain cancer and for the palliation of pain in bone metastasis.

220 estimable], p=0.0004) and median duration of palliation of pain intensity (4.2 months [95% CI 3.0-4.9

221 Palliation of pain interference (134 of 223 [60.1%] vs 3

222 38 of 100 [38.0%], p=0.0002; median time to palliation of pain interference 1.0 months [95% CI 0.9-1

223 Endoscopic approaches for diagnosis and palliation of pancreatic adenocarcinoma are rapidly expa

224 The surgical treatment and palliation of pancreatic cancer continues to advance.

225 Vinorelbine shows promise in the palliation of patients with malignant pleural mesothelio

226 patient received RF ablation for successful palliation of progressive follicular lymphoma adjacent t

227 egimen with an acceptable safety profile for palliation of recurrent SCCHN.

228 ods Patients for whom SCPC was performed for palliation of single ventricle disease who underwent che

229 For patients undergoing Fontan procedures as palliation of single ventricle physiology, the addition

230 e Fontan operation is performed for surgical palliation of single ventricle physiology.

231 diation therapy remains the mainstay of pain palliation of solitary lesions, bone-seeking radiopharma

232 mCi) per cycle is safe and offers effective palliation of symptoms and disease stabilization in pati

233 Management is aimed at palliation of symptoms and improvement in quality of lif

234 of therapy for many patients with cancer is palliation of symptoms common at the end of life, includ

235 d therapy has primarily been oriented toward palliation of symptoms related to organ involvement.

236 o make more informed choices, achieve better palliation of symptoms, and have more opportunity to wor

237 s discerned, but most patients had effective palliation of symptoms.

238 volves either transplantation (Tx) or staged palliation of the native heart.

239 patients, 217 (93%) never required surgical palliation of their primary tumor.

240 chose among them when undertaking endoscopic palliation of this difficult and rapidly rising disease.

241 Palliation of TOF with systemic-to-pulmonary artery shun

242 Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fr

243 terial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC

244 Hemodynamic stability after Norwood palliation often requires manipulation of pulmonary vasc

245 d with older age at the time of second-stage palliation, older age at pre-Fontan evaluation and femal

246 complex surgical atrial anatomy (ie, Fontan palliation or atrial switch procedure).

247 of LV hypoplasia, mandating single-ventricle palliation or cardiac transplantation.

248 decision making to direct care toward either palliation or more aggressive measures, such as tube fee

249 patients with LRRC treated with nonsurgical palliation or resection and identify predictors of poor

250 Patients with LRRC treated with nonsurgical palliation or resection experience significant levels of

251 of the approach, traditional surgical staged palliation or the hybrid procedure, survivals have vastl

252 Patients who received inotropes for palliation or those who preferred inotropes over LVAD ha

253 ia (P=0.003), male sex (P=0.01) and previous palliations (P=0.046) were associated with larger AO are

254 me loading throughout the surgical stages of palliation, particularly after the HF.

255 Despite significant improvements in palliation, patients' quality of life diminishes and the

256 , prevention, treatment, rehabilitation, and palliation) receive them, without undue financial hardsh

257 underlying pathophysiology leading to Fontan palliation, remodelling, or increased gravitational grad

258 Patients treated with nonsurgical palliation reported moderate to severe pain beyond the t

259 whether the type of shunt used at stage one palliation (S1P) affected the survival and the periopera

260 Outcome of stage 1 palliation (S1P) for hypoplastic left heart syndrome (HL

261 Survival to stage 2 palliation (S2P) was also significantly improved in the

262 The effect of the timing of stage 2 palliation (S2P), a physician-modifiable factor, on long

263 eart syndrome who underwent stage I surgical palliation (Sano: 11; Norwood: 73; Hybrid: 54) between 2

264 ment regarding the best strategy for stage I palliation should be reserved for an analysis of post-Fo

265 Conclusions By 6 years after staged palliation, shunt type has not impacted RV size and func

266 12 patients early (</=3 days) after Norwood palliation, simultaneous arterial, superior vena caval (

267 ng and mechanisms of myocardial injury among palliation strategies do not affect outcomes.

268 The relative economic impact of these palliation strategies is unknown.

269 Surgical palliation strategies were not identified as risk factor

270 All 3 palliation strategies, Norwood, Sano, and Hybrid, curren

271 on (SCPC) are lacking and may differ between palliation strategies.

272 dysfunction, and AVVR were equivalent among palliation strategies.

273 Surgical palliation strategy does not affect mortality, interstag

274 urvival and freedom from AVVR, regardless of palliation strategy.

275 While chemotherapy can achieve significant palliation, surgery may have a potential impact on long-

276 poplasia who have undergone single-ventricle palliation (SVP).

277 on and mortality, particularly after initial palliation to delay complete repair.

278 targeted therapy to progress beyond symptom palliation to early intervention for survival gain.

279 Surgical palliation to relieve systemic outflow obstruction is no

280 e intensive care unit, three (37%) initiated palliation, two (25%) documented the patient's code stat

281 rapy, supportive care drugs, and opioids for palliation uniformly available.

282 during early childhood after staged surgical palliations using echocardiography.

283 ontan failure at 10 and 20 years post-Fontan palliation was 91% (95% CI: 89% to 93%) and 77% (95% CI:

284 Stage II palliation was achieved in 92 (67%) patients (Sano: 7; N

285 Pain palliation was assessed in patients who had clinically s

286 3-dimensional computational model of hybrid palliation was developed by the finite volume method, al

287 Freedom from death/transplant after stage II palliation was equivalent between the groups (Norwood, 8

288 total of 1,468 patients who underwent Fontan palliation were identified; complete follow-up data were

289 d, n=32) who subsequently underwent stage II palliation were studied.

290 landmark of progress in non-chemotherapeutic palliation, when clearly we have not.

291 CMO included only symptom-palliation, whereas nonoperative therapy included all in

292 t stents are the first choice of therapy for palliation, which is safe and cost-effective, and they c

293 iation of systemic hypoxia, and avoidance of palliation with an arteriopulmonary shunt.

294 l-dependent pulmonary blood flow may undergo palliation with either a patent ductus arteriosus (PDA)

295 alternative to a surgical shunt for neonatal palliation with evidence for greater postprocedural stab

296 econstruction provide effective intermediate palliation with excellent late survival.

297 ctal-dependent pulmonary blood flow, initial palliation with patent ductus arteriosus (PDA) stent or

298 Palliation with platinum agent remains the standard of c

299 malignant adrenal tumors, both for cure and palliation, with low morbidity and mortality.

300 rtic homograft valve in the conduit, stage I palliation within the first year of our experience, and